Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies

NCT04092673 is registered in ClinicalTrials.gov with Effector Therapeutics as lead sponsor.

NCT NCT04092673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04092673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies
Lead sponsor
Effector Therapeutics
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 25, 2019
Completion date
March 31, 2025
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult